UNSPSC 51393106: Guanabenz monoacetate

This classification denotes an alpha-adrenergic agonist with the molecular formula C8H8Cl2N4.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 443O19GK1A, chemically known as hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)-, monoacetate, but more generally known as guanabenz monoacetate, which bears US NIH Compound Identifier 9570374. European Medicines Agency schedules guanabenz monoacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07978MIG.

Most nations, for tariff purposes, schedule guanabenz monoacetate under HS 29280090. SMILES: CC(=O)O.C1CC(C(C(C1)CL)/C=N/NC(=N)N)CL.

UNSPSC 51393106 Guanabenz monoacetate is a Commodity code that shows minimal alignment with recent state and local procurement activity. The two most recent opportunities tagged to this code—Seminole County, Florida's procurement of naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's request for information on direct-to-manufacturer prescription programs—involve pharmaceutical products and pharmacy benefit management rather than guanabenz monoacetate specifically. State and local governments do procure pharmaceutical products and medical supplies through competitive bidding and information-gathering processes, typically to support community health initiatives, emergency response, and employee or Medicaid beneficiary benefit programs, but the recent solicitations on record do not demonstrate active procurement of guanabenz monoacetate itself.

Seminole County's IFB (number IFB60459723LAS, posted June 30, 2026, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and includes E-Verify and drug-free workplace certification requirements. The Texas HHS RFI (number HHS0017013, posted April 3, 2026) explores vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows no current market signals for guanabenz monoacetate procurement at the state or local level.